Current Urology Reports

, 17:86 | Cite as

Focal Therapy for Prostate Cancer: Pending Questions

  • Xavier CathelineauEmail author
  • Rafael Sanchez-Salas
Invited Commentary


Focal therapy (FT) represents a potential shift in clinical practice by featuring a tissue-sparing approach for prostate cancer (PCa) treatment. It stands midway between active surveillance (AS) and more aggressive options like radical prostatectomy (RP) or radiotherapy. The field has enormously evolved in the last few years but there are still pending questions to answer in the future. The manuscript overlooks FT in terms of indications, available energies, situation of tumor microenvironment, follow-up, re-interventions, and the future of this approach for PCa.


Focal therapy Prostate cancer Treatment Radical prostatectomy 


Compliance with Ethical Standards

Conflict of Interest

Xavier Cathelineau and Rafael Sanchez-Salas each declare no potential conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


  1. 1.
    Onik G, Narayan P, Vaughan D, Dineen M, Brunelle R. Focal “nerve-sparing” cryosurgery for treatment of primary prostate cancer: a new approach to preserving potency. Urology. 2002;60(1):109–14.CrossRefPubMedGoogle Scholar
  2. 2.
    Onik G, Vaughan D, Lotenfoe R, Dineen M, Brady J. The “male lumpectomy”: focal therapy for prostate cancer using cryoablation results in 48 patients with at least 2-year follow-up. Urol Oncol. 2008;26(5):500–5.CrossRefPubMedGoogle Scholar
  3. 3.
    de la Rosette J, Ahmed H, Barentsz J, Johansen TB, Brausi M, Emberton M, et al. Focal therapy in prostate cancer-report from a consensus panel. J Endourol. 2010;24(5):775–80.CrossRefPubMedGoogle Scholar
  4. 4.
    Donaldson IA, Alonzi R, Barratt D, Barret E, Berge V, Bott S, et al. Focal therapy: patients, interventions, and outcomes—a report from a consensus meeting. Eur Urol. 2015;67(4):771–7.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Muller BG, van den Bos W, Pinto PA, de la Rosette JJ. Imaging modalities in focal therapy: patient selection, treatment guidance, and follow-up. Curr Opin Urol. 2014;24(3):218–24.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Linares Espinós E, Barret E, Sivaraman A, Pérez-Reggeti JI, Sánchez-Salas R, Rozet F, Galiano M, Cathelineau X. Localized prostate cancer Focal Therapy: “A la carte” Model. Arch Esp Urol. 2016Google Scholar
  7. 7.
    Lindner U, Weersink RA, Haider MA, Gertner MR, Davidson SR, Atri M, et al. Image guided photothermal focal therapy for localized prostate cancer: phase I trial. J Urol. 2009;182(4):13717.CrossRefGoogle Scholar
  8. 8.
    Gladwell, Malcolm. The tipping point – How little things can make a difference. Ed. Little, Brown and Company (2000). Print.Google Scholar
  9. 9.
    Walz J et al. Committee1 Diagnosis of Prostate Cancer and Selection for Focal Therapy. In: Image-Guided Therapies for Prostate and Kidney Cancers. A Joint SIU-ICUD International Consultation. Sanchez-Salas, R and Desai, M. [eds.] Melbourne, Australia. October 15–18. Available at: Forthcoming October 2016.
  10. 10.
    van der Poel H, Klotz L, Andriole G, Azzouzi AR, Bjartell A, Cussenot O, et al. Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers. World J Urol. 2015;33(7):907–16. doi: 10.1007/s00345-015-1603-7.Epub2015Jun.CrossRefPubMedGoogle Scholar
  11. 11.
    Ahmed HU, Dickinson L, Charman S, Weir S, McCartan N, Hindley RG, et al. Focal ablation targeted to the index lesion in multifocal localised prostate cancer: a prospective development study. Eur Urol. 2015;68(6):927–36. doi: 10.1016/j.eururo.2015.01.030.CrossRefPubMedGoogle Scholar
  12. 12.
    Postema AW, De Reijke TM, Ukimura O, Van den Bos W, Azzouzi AR, Barret E, Baumunk D, Blana A, Bossi A, Brausi M, Coleman JA, Crouzet S, Dominguez-Escrig J, Eggener S, Ganzer R, Ghai S, Gill IS, Gupta RT, Henkel TO, Hohenfellner M, Jones JS, Kahmann F, Kastner C, Köhrmann KU, Kovacs G, Miano R, van Moorselaar RJ, Mottet N, Osorio L, Pieters BR, Polascik TJ, Rastinehad AR, Salomon G, Sanchez-Salas R, Schostak M, Sentker L, Tay KJ, Varkarakis IM, Villers A, Walz J, De la Rosette JJ. Standardization of definitions in focal therapy of prostate cancer: report from a Delphi consensus project. World J Urol. 2016 Feb 18.Google Scholar
  13. 13.
    Muller BG, van den Bos W, Brausi M, Fütterer JJ, Ghai S, Pinto PA, et al. Follow-up modalities in focal therapy for prostate cancer: results from a Delphi consensus project. World J Urol. 2015;33(10):1503–9. doi: 10.1007/s00345-014-1475-2.CrossRefPubMedGoogle Scholar
  14. 14.
    van den Bos W, Muller BG, Ahmed H, Bangma CH, Barret E, Crouzet S, et al. Focal therapy in prostate cancer: international multidisciplinary consensus on trial design. Eur Urol. 2014;65(6):1078–83. doi: 10.1016/j.eururo.2014.01.001.CrossRefPubMedGoogle Scholar
  15. 15.
    Muller BG, Fütterer JJ, Gupta RT, Katz A, Kirkham A, Kurhanewicz J, et al. The role of magnetic resonance imaging (MRI) in focal therapy for prostate cancer: recommendations from a consensus panel. BJU Int. 2014;113(2):218–27. doi: 10.1111/bju.12243.CrossRefPubMedGoogle Scholar
  16. 16.
    Ho R, Siddiqui MM, George AK, Frye T, Kilchevsky A, Fascelli M, et al. Preoperative multiparametric magnetic resonance imaging predicts biochemical recurrence in prostate cancer after radical prostatectomy. PLoS One. 2016;11(6):e0157313. doi: 10.1371/journal.pone.0157313.eCollection 2016.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Barret et al. Committee 3 Imaging in localized Prostate Cancer. Multiparametric Magnetic Resonance Imaging. In: Image-Guided Therapy for Prostate and Kidney Cancers. A Joint SIU-ICUD International Consultation. Sanchez-Salas, R and Desai, M. [eds.] Melbourne, Australia. October 15–18, 2015. Available at: Forthcoming October 2016.
  18. 18.
    Moore CM, Robertson NL, Arsanious N, Middleton T, Villers A, Klotz L, et al. Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. Eur Urol. 2013;63(1):125–40.CrossRefPubMedGoogle Scholar
  19. 19.
    Siddiqui MM, George AK, Rubin R, Rais-Bahrami S, Parnes HL, Merino MJ, Simon RM, Turkbey B, Choyke PL, Wood BJ, Pinto PA. Efficiency of Prostate Cancer Diagnosis by MR/Ultrasound Fusion-Guided Biopsy vs Standard Extended-Sextant Biopsy for MR-Visible Lesions. J Natl Cancer Inst. 2016 Apr 29;108(9). pii: djw039. doi: 10.1093/jnci/djw039. Print 2016 Sep.
  20. 20.
    Konety et al. Committee 3 Prostatic biopsies: available techniques and approaches. In: Image-Guided Therapy for Prostate and Kidney Cancers. A Joint SIU-ICUD International Consultation. Sanchez-Salas, R and Desai, M. [eds.] Melbourne, Australia. October 15–18, 2015. Available at: Forthcoming October 2016.
  21. 21.
    Barret E, Ahallal Y, Sanchez-Salas R, Galiano M, Cosset JM, Validire P, et al. Morbidity of focal therapy in the treatment of localized prostate cancer. Eur Urol. 2013;63(4):618–22. doi: 10.1016/j.eururo.2012.11.057.CrossRefPubMedGoogle Scholar
  22. 22.
    Perez-Reggeti JI, Sanchez-Salas R, Sivaraman A, Linares Espinos E, de Gracia-Nieto AE, Barret E, Galiano M, Rozet F, Fregeville A, Renard-Penna R, Cathala N, Mombet A, Prapotnich D, Cathelineau X. High intensity focused ultrasound with Focal-One® device: Prostate-specific antigen impact and morbidity evaluation during the initial experience. Actas Urol Esp. 2016 Aug 16.Google Scholar
  23. 23.
    Durand M, Barret E, Galiano M, Rozet F, Sanchez-Salas R, Ahallal Y, Macek P, Gaya JM, Cerruti J, Devilliers H, Loeffler J, Amiel J, Vallancien G, Cathelineau X. Focal cryoablation: a treatment option for unilateral low-risk prostate cancer.Google Scholar
  24. 24.
    Cosset JM, Cathelineau X, Wakil G, Pierrat N, Quenzer O, Prapotnich D, et al. Focal brachytherapy for selected low-risk prostate cancers: a pilot study. Brachytherapy. 2013;12(4):331–7.CrossRefPubMedGoogle Scholar
  25. 25.
    De la Rosette T et al. Committee 4 Available Ablation Energies to Treat Prostate Cancer. In: Image-Guided Therapy for Prostate and Kidney Cancers. A Joint SIU-ICUD International Consultation. Sanchez-Salas, R and Desai, M. [eds.] Melbourne, Australia. October 15–18, 2015. Available at: Forthcoming October 2016.
  26. 26.
    Sivaraman A, Barret E. Focal therapy for prostate cancer: an “À la Carte” approach. Eur Urol. 2016;69(6):973–5.CrossRefPubMedGoogle Scholar
  27. 27.
    Stern JM, Kibanov Solomonov VV, Sazykina E, Schwartz JA, Gad SC, Goodrich GP. Initial evaluation of the safety of nanoshell-directed photothermal therapy in the treatment of prostate disease. Int J Toxicol. 2016;35(1):38–46. doi: 10.1177/1091581815600170.CrossRefPubMedGoogle Scholar
  28. 28.
    Preise D, Scherz A, Salomon Y. Antitumor immunity promoted by vascular occluding therapy: lessons from vascular-targeted photodynamic therapy (VTP). Photochem Photobiol Sci. 2011;10(5):681–8. doi: 10.1039/c0pp00315h.CrossRefPubMedGoogle Scholar
  29. 29.
    Azzouzi AR, Barret E, Bennet J, Moore C, Taneja S, Muir G, et al. TOOKAD® soluble focal therapy: pooled analysis of three phase II studies assessing the minimally invasive ablation of localized prostate cancer. World J Urol. 2015;33(7):945–53.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Hu J, Xu H, Zhu W, et al. Neo-adjuvant hormone therapy for non-metastatic prostate cancer: a systematic review and meta-analysis of 5194 patients. World J Surg Oncol. 2015;13:73.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Cussenot O, Cornu JN, Drouin SJ, Mozer P, Egrot C, Vaessen C, et al. Secondary chemoprevention of localized prostate cancer by short-term androgen deprivation to select indolent tumors suitable for active surveillance: a prospective pilot phase II study. World J Urol. 2014;32(2):545–50. doi: 10.1007/s00345-013-1196-y.CrossRefPubMedGoogle Scholar
  32. 32.
    Barret E, Harvey-Bryan KA, Sanchez-Salas R, Rozet F, Galiano M, Cathelineau X. How to diagnose and treat focal therapy failure and recurrence? Curr Opin Urol. 2014;24(3):241–6.CrossRefPubMedGoogle Scholar
  33. 33.
    Valerio M, Ahmed HU, Emberton M, Lawrentschuk N, Lazzeri M, Montironi R, et al. The role of focal therapy in the management of localised prostate cancer: a systematic review. Eur Urol. 2014;66(4):732–51.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Polascik T et al. Committee 5 Surveillance after Focal Therapy. In: Image-Guided Therapy for Prostate and Kidney Cancers. A Joint SIU-ICUD International Consultation. Sanchez-Salas, R and Desai, M. [eds.] Melbourne, Australia. October 15–18, 2015. Available at: Forthcoming October 2016.
  35. 35.
    Linares Espinós E, Sánchez-Salas R, Sivaraman A, Perez-Reggeti JI, Barret E, Rozet F, et al. Minimally invasive salvage prostatectomy after primary radiation or ablation treatment. Urology. 2016;94:111–6.CrossRefPubMedGoogle Scholar
  36. 36.
    Duijzentkunst DA, Peters M, van der Voort van Zyp JR, Moerland MA, van Vulpen M .Focal salvage therapy for local prostate cancer recurrences after primary radiotherapy: a comprehensive review. World J Urol. 2016 Mar 24. [Epub ahead of print].Google Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Department of UrologyL’Institut Mutualiste MontsourisParis Cedex 14France

Personalised recommendations